Insulin degludec_Liraglutide(1)

Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.

Patients with type 2 diabetes last for longer before needing treatment intensification if they are treated with fixed-ratio combination insulin degludec and liraglutide rather than insulin glargine 100 U/mL, show the DUAL VIII findings.

Findings from the DUAL IX trial suggest that the addition of insulin degludec/liraglutide to SGLT2 inhibitor therapy results in better glycemic control than add-on insulin glargine among insulin-naïve patients with uncontrolled type 2 diabetes.

IDegLira, which combines the basal insulin degludec with the glucagon-like peptide-1 receptor agonist liraglutide, improves glycemic control within 6 months of initiation irrespective of previous therapy, real-world study data show.

Study results presented at the EASD annual meeting in Lisbon, Portugal, demonstrated the potential of several novel therapies for the treatment of obesity-related metabolic dysfunction and type 2 diabetes.

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

Research shows that a fixed-dose combination of insulin degludec and liraglutide is as effective as a basal–bolus insulin regimen in insulin-dependent patients with type 2 diabetes, and requires just one daily injection.